Outpace Bio
Rupesh Amin is a seasoned professional in the field of cancer immunotherapy, currently serving as Senior Director for the CAR T Pipeline at Outpace Bio since March 2023. Prior to this role, Rupesh held the position of Director for the Advanced Technologies Group at Century Therapeutics, LLC, where work focused on engineering allogeneic T and NK cells using the iPSC platform. Rupesh's experience includes serving as Associate Director at Bristol-Myers Squibb, leading initiatives to enhance CAR T cell therapies, and as a Senior Scientist at Juno Therapeutics, Inc., focused on developing innovative cancer immunotherapies. Early research contributions were made during postdoctoral fellowships at Fred Hutch and UC Berkeley, where Rupesh explored stem cell mechanisms and B-cell development, respectively. Rupesh Amin holds a Ph.D. in Molecular Biology/Immunology from the University of California, Berkeley, and a B.S. in Biochemistry and Molecular Biology from the University of Arizona.
This person is not in any teams
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.